



Kisolite Shareholder Update – Interim President’s Report

FOR IMMEDIATE RELEASE

Chilliwack, BC, Canada – March 13, 2019 - Kisolite Corp., Kisolite Corp, the exclusive marketer of all natural “Kisolite”, is pleased to report that final terms on our first Licensing Agreement for topical, non-medicinal soap products is being prepared for signature, and expected to be announced shortly.

Since November 2018 the company has entered into product development work with Dr. Neil Branda and Dr. Dirk Lange for formulations of Kisolite that will be specific to target markets, commencing with topical applications for skin disease. During 2019 product testing will be occur at 4D Labs at Simon Fraser University, Vancouver General Hospital, and the University of Ottawa.

Commencing last November 2019 Nutrasource Pharmaceutical and Nutraceutical Services (Guelph, Ontario), a leader in product certification, has completed safety analysis and dosage calculations for ‘Kisolite’ as part of the Master File application to Health Canada for a Natural Health Product (NHP) certification. If approved, Kisolite would then be approved for sale as a nutraceutical.

Additionally, extraction operations are scheduled to get underway at Kisameet Bay this April 2019; production in the Squamish facility has resulted in an inventory of finished powdered mineral clay for export; and negotiations to move to a larger commercial facility in Squamish in August 2019 are nearly complete.

The Company has undertaken an interim-closing for its most recent private placement.

“Following a start-up period, commencing late last year, Kisolite Corp. is on-track and on-schedule to fulfill its 2019 Business Plan” stated Kisolite’s President, Lawry Lund.

About Kisolite Corp

Kisolite Corp owns the exclusive rights to Kisolite for Licensing Agreements, supply, product development, formulations, research, sales and marketing. The company is undertaking commercialization and product development for a broad range of applications extending from cosmetics through to applications for both human and animal health.

For further detailed information please visit Kisolite Corp’s website at www.kisolite.com .



On behalf of the Board:

Lawry Lund - President
Kisolite Corp.

Investor Inquiries:

North America Toll Free: 888-519-0665

Email: Info@Kisolite.com

This press release may contain forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or "recurring" or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors, such as demand for the Company's products, currency exchange changes and risks, internal funding and the financial condition of the Company, product roll-out, competition, technological changes, and other commercial matters involving the Company, its products, and the markets in which the Company operates, as well as general economic conditions, which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this press release. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. However, any further disclosures made on related subjects in subsequent reports should be consulted.